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Abstract
Exocrine pancreatic insufficiency (EPI) and resultant maldigestion occurs in up to 80% of patients
following gastric, duodenal or pancreatic surgery. Accurate diagnosis is required to determine the
appropriate intervention, but the conventional method of faecal fat quantification is time-consuming and
not always readily available. The optimized 13C-mixed triglyceride (13C-MTG) breath test is an accurate
alternative post-surgery. Pancreatic enzyme replacement therapy (PERT) is indicated post-surgery in
patients with clinically evident steatorrhoea, weight loss or maldigestion-related symptoms. Given its
favourable safety profile, PERT is also appropriate in asymptomatic patients with high faecal fat excretion
as such patients are at high risk for nutritional deficits. However, published data evaluating PERT in
this setting are limited. Uncoated powder preparations may be preferred in cases of low gastric acidity
and partial or total gastric resection. In clinical studies, enteric-coated microspheres were associated
with greater weight gain after surgery vs. uncoated preparations. This was confirmed in a recent study
using the 13C-MTG breath test; fat absorption increased from <40% without therapy to almost 60% with
enteric-coated minimicrospheres (40 000 lipase units/meal), with >60% of patients achieving normal
breath test results (i.e. normal fat digestion) during PERT. A therapeutic algorithm for the treatment of EPI
after surgery is also discussed.
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Introduction
Exocrine pancreatic insufficiency (EPI) is a common and severe
complication of different pancreatic as well as extra-pancreatic
diseases. Acute necrotizing pancreatitis, chronic pancreatitis,
cystic fibrosis and pancreatic cancer are well-known causes of
EPI.1 Measurements of faecal levels of pancreatic elastase have
indicated that diabetes mellitus leads to impaired pancreatic
secretion and potentially to EPI.2 The possibility of exocrine insuf-
ficiency should also be considered in extra-pancreatic conditions,
such as coeliac disease and Crohn’s disease.3,4 Because they distort
normal anatomy and consequently alter digestive physiology,
gastric, duodenal and pancreatic surgeries are important causes of
maldigestion in themselves. The present article reviews the patho-
physiology, clinical consequences, diagnosis and therapy of EPI
after gastrointestinal (GI) and pancreatic surgery.
Physiology
Gastric emptying of nutrients is regulated by fundus relaxation,
antral motility and the motor activity of the pylorus. These func-
tions are tightly regulated by antro-fundic reflexes (fundus relax-
ation secondary to the presence of nutrients in the gastric antrum)
and duodenogastric reflexes (fundus relaxation and inhibition
of antral motility as a consequence of the presence of nutrients
within the duodenal lumen) (Fig. 1). In this way, only particles
sized <2 mm are able to pass through the pylorus and thus
nutrients reach the duodenum in a slow and progressive manner.
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This allows pancreatic secretions to exert digestive activity at the
appropriate site.
Post-prandial pancreatic secretion is first neurally stimulated
by fundus relaxation, which triggers a vagal reflex (neurally medi-
ated post-prandial stimulation of exocrine pancreatic secretion).
Thereafter, the release of cholecystokinin (CCK) in response to the
nutrient-stimulated duodenal secretion of CCK-releasing peptide
represents the major hormone-mediated post-prandial stimula-
tion of exocrine pancreatic secretion (Fig. 1).
Pathophysiology
Anatomical changes secondary to GI and pancreatic surgery
lead to important physiological alterations that frequently cause
maldigestion. Total or partial resections of the stomach, with
or without duodenal resection (e.g. in the context of the Whipple
procedure), as well as partial pancreatic resection, are associated
with the following events: (i) disturbance of fundus relaxation
caused by the disappearance of antro-fundic and duodeno-fundic
reflexes; (ii) absence of neurally stimulated pancreatic secretion
caused by the lack of fundus relaxation; (iii) reduction in CCK-
mediated stimulation of pancreatic secretion secondary to duode-
nal resection; (iv) large and hard-to-digest nutrient particles
reaching the jejunal lumen because of resection of the distal
stomach; (v) reduction in exocrine pancreatic secretion in cases of
pancreatic resection; and (vi) asynchrony between the gastric
emptying of nutrients and bilio-pancreatic secretion as a result of
anatomical reconstruction.
A previous study by Ito supported these findings by demon-
strating an abnormally low post-prandial CCK release after
duodenopancreatectomy, but not after duodenum-preserving
pancreatic head resection.5 Low CCK release is in turn associated
with abnormal exocrine pancreatic function, as measured by the
N-benzoyl-l-tyrosyl-p-aminobenzoic acid (BT-PABA) test.5 All of
the alterations mentioned above are responsible for primary and
secondary EPI. As a consequence, maldigestion develops in up
to 80% of patients who have been operated upon for gastric or
pancreatic diseases.6–8
Diagnosis
Diagnosis of maldigestion is highly relevant in patients after gas-
troduodenal or pancreatic resection in order to evaluate the need
for oral pancreatic enzyme replacement therapy (PERT). Faecal
elastase has been used frequently to evaluate pancreatic exocrine
function after pancreatic surgery, mainly pancreatoduodenec-
tomy.9 However, that faecal elastase is a measure of pancreatic
secretion must be taken into account, whereas other factors like
the asynchrony between the gastric emptying of nutrients and
pancreatic secretion, which cannot be evaluated by quantification
of faecal elastase, also play a key role in maldigestion after surgery.
Faecal chymotrypsin has also been used by other authors10 to
evaluate the frequency of EPI after different pancreatic surgical
procedures, but again faecal chymotrypsin reflects only pancreatic
secretion and not digestion.
Fat digestion in this setting is best evaluated by the quantifica-
tion of the coefficient of fat absorption by assessing faecal fat,
using either the standard Van de Kamer test or the more recent
near infrared analysis. An exact evaluation of the fat ingested is
required for this purpose, which frequently requires the patient
to be admitted to hospital for 5 days for the test to be performed.
As an alternative, maldigestion secondary to gastroduodenal and
pancreatic surgery can be accurately evaluated by means of the
optimized 13C-mixed triglyceride (13C-MTG) breath test.11 In this
context, it is critical that the test is performed as previously opti-
mized, mainly in terms of substrate dose, fat content of the test
meal, pre-test oral administration of metoclopramide, and timing
and duration of breath sample collection.12–14 Using this test,
we have recently demonstrated that up to 82% of patients suffer
from fat maldigestion after the Whipple procedure or pylorus-
preserving pancreatoduodenectomy (Domínguez-Muñoz et al.,
unpublished data, 2009).
Ideally, the ability to routinely assess the coefficient of fat
absorption by faecal fat quantification or to perform the 13C-MTG
breath test should be widely available in clinical practice. This is
important not only in testing for EPI, but also in objectively
evaluating the efficacy of oral PERT.14 However, as the vast major-
ity of patients develop fat maldigestion after duodenopancreate-
ctomy, the prescription of oral pancreatic enzyme supplements
in all these patients should be recommended in centres where the
evaluation of fat digestion is not readily available.
Therapy
PERT is indicated in patients who have undergone GI surgery
with clinically evident steatorrhoea, weight loss or maldigestion-
related symptoms. Whether asymptomatic patients with an
abnormally high daily faecal fat excretion are candidates for sub-
stitution therapy is debatable. The fact that these patients are at
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Figure 1 Mechanisms of control of post-prandial gastric and pan-
creatic function. CCK, cholecystokinin; CCK-RP, cholecystokinin-
releasing peptide
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high risk for developing nutritional deficits represents an indica-
tion for replacement therapy in this situation, which is supported
by evidence of the safety of oral pancreatic enzyme preparations.
Thus, the vast majority of patients undergoing any type of GI and
pancreatic resection will require oral PERT.
Despite the relevance of EPI in assessing the nutritional status
of patients who have had surgery, the number of studies evaluat-
ing the usefulness of PERT in this setting is limited and data
regarding the best preparation to be used are scarce.15 Uncoated
powder preparations may be preferred in cases of low gastric
acidity and partial or total gastric resection, although enteric-
coated enzyme microspheres have been shown to be associated
with a higher body weight gain compared with uncoated prepa-
rations in patients after duodenopancreatectomy.16 In fact, body
weight after surgery increases very slowly when uncoated enzymes
are used, whereas a much more relevant increase in body weight
is obtained by the oral administration of enteric-coated prepa-
rations in the form of microspheres (Fig. 2).16 Another study has
supported the finding that oral enzyme replacement therapy
in the form of enteric-coated microspheres is highly effective in
treating post-surgical fat maldigestion.17 We have recently con-
firmed these data using the 13C-MTG breath test. The proportion
of fat digested and absorbed as measured by the 13C-MTG breath
test increases from <40%without therapy to almost 60% on PERT
in the form of enteric-coated minimicrospheres at a dose of
40 000 units (U) of lipase/meal and 20 000 U lipase/snack (i.e.
160 000 U lipase/day consumed in the course of three main meals
plus two snacks). Almost 60% of patients are able to achieve a
normal breath test result (i.e. indicating normal fat digestion)
during this replacement therapy, whereas higher doses of enzymes
(80 000–100 000 U lipase/meal and 40 000–50 000 U lipase/snack
for a total of 400 000 U lipase/day) may be required in other
patients. If gastric acid secretion is preserved, the addition of a
proton pump inhibitor improves the therapeutic efficacy of oral
pancreatic enzymes in patients with insufficient response to
therapy despite the administration of high doses of oral pancreatic
enzymes.1 Finally, testing for bacterial overgrowth and treating if
positive, and the addition of loperamide, may help in reducing
steatorrhoea in patients with abnormal fat digestion despite high
doses of enzymes and the addition of a proton pump inhibitor.1
A therapeutic algorithm for the management of EPI after gas-
troduodenal or pancreatic surgery is summarized in Fig. 3.
Disclosure
This supplement is supported by Solvay Pharmaceuticals Market-
ing and Licensing AG, Allschwill, Switzerland. Editorial assistance
was provided by Helen Varley PhD, Envision Scientific Solutions,
Horsham, UK and supported by Solvay Pharmaceuticals Market-
ing and Licensing AG.
Conflicts of interest
Dr Domínguez-Muñoz has acted as an occasional consultant for Solvay
Pharmaceuticals.
References
1. Domínguez-Muñoz JE. (2007) Pancreatic enzyme therapy for pancreatic
exocrine insufficiency. Curr Gastroenterol Rep 9:116–122.
2. Ewald N, Raspe A, Kaufmann C, Bretzel RG, Kloer HU, Hardt PD. (2009)
Determinants of exocrine pancreatic function as measured by fecal
elastase-1 concentrations (FEC) in patients with diabetes mellitus. Eur J
Med Res 14:118–122.
3. Leeds JS, Hopper AD, Hurlstone DP, Edwards SJ, McAlindon ME,
Lobo AJ et al. (2007) Is exocrine pancreatic insufficiency in adult coeliac
disease a cause of persisting symptoms? Aliment Pharmacol Ther 25:
265–271.
4. Seibold F, Scheurlen M, Müller A, Jenss H, Weber P. (1996) Impaired
pancreatic function in patients with Crohn's disease with and without
pancreatic autoantibodies. J Clin Gastroenterol 22:202–206.
5. Ito K. (2005) Duodenum preservation in pancreatic head resection to
52.8
54.9
58.0
50
52
54
56
58
60
0              6             12            18            24             30
Months after surgery
B
o
d
y 
w
ei
g
h
t,
 k
g
Enteric-coated
microspheresPancreatin powder
P < 0.01 P < 0.05
Figure 2 Changes in body weight after duodenopancreatectomy. A
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Figure 3 Therapeutic algorithm for exocrine pancreatic insufficiency
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